Kane Biotech Announces New Private Placement Offering

Rhea-AI Summary

Kane Biotech (OTC:KNBIF) announced a non‑brokered private placement to issue up to 16 million common shares at $0.05 per share for gross proceeds of up to $800,000. Proceeds are intended for working capital and general corporate purposes. Certain insiders may participate. Closing is expected on or about December 17, 2025. All issued shares will be subject to a four‑month and one‑day hold period. The Offering is subject to necessary approvals, including the TSX Venture Exchange. Securities will not be registered in the United States and may not be offered or sold in the U.S. or to U.S. persons.

Positive

• Raises up to $800,000 to bolster liquidity
• Proceeds designated for working capital and general corporate purposes
• Four‑month and one‑day hold limits immediate resale

Negative

• Issuance of up to 16 million shares may dilute existing shareholders
• Insiders may participate, potentially increasing insider ownership concentration
• Closing and funding subject to TSX Venture Exchange approval

Key Figures

Shares offered up to 16,000,000 shares Non-brokered private placement

Offering price $0.05 per share Private placement terms

Gross proceeds up to $800,000 Maximum capital raised from offering

Expected closing date December 17, 2025 Targeted closing of private placement

Hold period four months and one day Restriction on resale of offering shares

Securities act year 1933 United States Securities Act of 1933 reference

Market Reality Check

$0.0273 Last Close

Volume Volume 101,700 is about 4.7x the 20-day average of 21,631 shares. high

Technical Shares traded below the 200-day MA, which is at $0.08 pre-announcement.

Peers on Argus

Pre-offering, KNBIF was up 6.4% with elevated volume, while key biotech peer ORGS gained 38.88% and other peers were flat, suggesting stock-specific dynamics rather than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 10	Regulatory approval	Positive	+6.4%	Health Canada approved revyve Antimicrobial Wound Gel Spray for Canada.
Nov 04	Clinical data update	Positive	-24.8%	Strong revyve wound data with high PAR and pathogen reduction presented at conferences.
Sep 16	Regulatory submission	Positive	+20.1%	FDA 510(k) submission for revyve Antimicrobial Wound Cleanser in U.S. market.
Aug 28	Earnings update	Negative	+13.6%	Q2 2025 revenue dropped sharply and PrairiesCan default notice highlighted balance-sheet strain.
Jul 14	Conference presentation	Neutral	-5.1%	Announcement of CEO presentation at Advanced Wound Care Summit USA.

Pattern Detected

Recent history shows mixed reactions, with 3 divergences and 2 alignments between news tone and next-day price moves.

Recent Company History

Over the last six months, Kane Biotech reported weak Q2 2025 revenue of $27,997 and a smaller net loss, presented revyve wound-care data with strong efficacy, and advanced regulatory milestones including an FDA 510(k) submission and later Health Canada approval for revyve Wound Gel Spray. Market reactions alternated between gains and selloffs, indicating inconsistent pricing of positive developments. Today’s financing announcement follows this backdrop of clinical and regulatory progress paired with financial constraints.

Market Pulse Summary

This announcement details a non-brokered private placement of up to 16 million shares at $0.05, for gross proceeds of up to $800,000, to fund working capital and general purposes. It follows recent regulatory and clinical progress for the revyve wound-care portfolio and earlier disclosure of financial strains in Q2 2025. Investors may monitor execution on closing by December 17, 2025, insider participation, and how added capital supports ongoing product and regulatory milestones.

Key Terms

non-brokered private placement financial

"its intention to undertake a non-brokered private placement offering"

A non-brokered private placement is when a company raises money by selling securities (such as shares or bonds) directly to a small group of chosen investors without using a broker or dealer as a middleman. For investors it matters because it can provide faster, lower-cost access to new investment opportunities but may bring higher risk, less liquidity and potential dilution of existing holdings compared with public offerings.

private placement offering financial

"intention to undertake a non-brokered private placement offering (the “Offering”)"

A private placement offering is when a company sells its stock or bonds directly to a small group of investors instead of offering them to the general public. This allows the company to raise money quickly and privately, often for specific projects or needs, without going through a public stock exchange.

hold period financial

"subject to a hold period of four-months and one day from the date"

A hold period is a specific span of time during which an investor is required or expected to keep a security or asset and cannot freely sell it or realize its value. It matters because it limits liquidity and can affect tax treatment, risk exposure and timing of gains or losses—like a cooling-off or fixed-term commitment that prevents you from quickly cashing out even if market conditions change.

tsx venture exchange financial

"including the approval of the TSX Venture Exchange"

A junior stock exchange in Canada where smaller, early-stage companies list shares to raise capital and gain public visibility. Think of it as a farmers’ market for young businesses: it offers investors a chance to buy into fast-growing but higher-risk ventures, with looser listing rules and typically lower liquidity than major exchanges. It matters because performance and financing on this exchange can signal growth prospects or risk for investors.

united states securities act of 1933 regulatory

"not been, and will not be, registered under the United States Securities Act of 1933"

A federal law that requires companies to provide clear, written information when they sell stocks, bonds or other investment securities to the public, and that outlaws misleading claims or fraud in those offerings. It matters to investors because it forces sellers to lay out the key facts — like a detailed menu for an unfamiliar restaurant — so buyers can compare options, understand risks, and rely on a legal framework if important information is omitted or deceptive.

AI-generated analysis. Not financial advice.

Not for distribution to U.S. news wire services or dissemination in the United States

WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of $0.05 per Share for gross proceeds of up to $800,000.

The net proceeds of the Offering will be used for working capital and general corporate purposes. Certain insiders of Kane Biotech may participate in the Offering. Closing of the Offering is expected to take place on or about December 17, 2025.

All Shares issued in connection with the Offering are subject to a hold period of four-months and one day from the date of issuance.

The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

About Kane Biotech Inc. (TSX-V: KNE)

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve^® addresses both biofilms and wound bacteria. revyve^® Antimicrobial Wound Gel and revyve^® Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. revyve^® Antimicrobial Wound Gel is Health Canada approved. To learn more about revyve, visit revyvegel.com or revyvegel.ca.

Join Kane’s Distribution List & Social Media:

To stay informed on the latest developments, sign-up for the Company’s email distribution list HERE.

Follow Kane

Website: kanebiotech.com

LinkedIn: https://www.linkedin.com/company/kanebiotech/

Presentations: https://kanebiotech.com/publications-posters/

For more information:
Dr. Robert Huizinga	Ray Dupuis
Interim CEO	Chief Financial Officer
Kane Biotech Inc.	Kane Biotech Inc.
rhuizinga@kanebiotech.com	rdupuis@kanebiotech.com
(780) 970-1100	(204) 298-2200

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

FAQ

What is Kane Biotech's private placement size and price (KNBIF)?

Kane Biotech intends to issue up to 16 million shares at $0.05 per share for gross proceeds up to $800,000.

When is the expected closing date for Kane Biotech's Offering (KNBIF)?

The Offering is expected to close on or about December 17, 2025, subject to required approvals.

How will Kane Biotech use the funds from the private placement (KNBIF)?

The net proceeds are earmarked for working capital and general corporate purposes.

Will shares from Kane Biotech's private placement be immediately tradable (KNBIF)?

No; all shares issued under the Offering are subject to a four‑month and one‑day hold period.

Can U.S. investors participate in Kane Biotech's private placement (KNBIF)?

No; the securities will not be registered under the U.S. Securities Act and may not be offered or sold in the U.S. or to U.S. persons.

Does Kane Biotech require regulatory approval for the private placement (KNBIF)?

Yes; the Offering is subject to receipt of all necessary approvals, including the TSX Venture Exchange.